GENI vs SRAD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

GENI

61.3
AI Score
VS
GENI Wins

SRAD

36.8
AI Score

Investment Advisor Scores

GENI

61score
Recommendation
HOLD

SRAD

37score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric GENI SRAD Winner
Forward P/E 51.8135 31.8471 SRAD
PEG Ratio 0 0 Tie
Revenue Growth 62.3% 24.1% GENI
Earnings Growth 0.0% -61.6% GENI
Tradestie Score 61.3/100 36.8/100 GENI
Profit Margin -18.9% 1.5% SRAD
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY GENI

Relative Price Performance (Last 90 Days)

GENI 1M: -1.5% · 3M: -28.0% SRAD 1M: +11.0% · 3M: -6.6%

Current Technical Phase

GENI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 44

RSI (14): 43.9 · Price: $6.04

SRAD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.4 · Price: $12.91

Fundamentals Snapshot

Metric GENI SRAD
Market Cap — —
Forward P/E 6.0 32.4
Trailing P/E — 191.0
Revenue (TTM) — —
Revenue Growth 0.6% 0.2%
Gross Margin 0.3% 0.3%
Operating Margin 0.1% 0.2%
EPS -0.61 0.07
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GENI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.